Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Appili Therapeutics Inc
APLIF
Primary Symbol:
T.APLI
Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical...
antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:APLI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(3216)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Oct 07, 2021 8:30am
IIROC Trading Halt
TORONTO, Oct. 7, 2021 /CNW/ - The following issues have been halted by IIROC: Company: Appili Therapeutics Inc. TSX Symbol: APLI All Issues: Yes Reason: Pending News Halt Time (ET)
...more
(3216)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Oct 06, 2021 5:04pm
Overnight Marketed Equity Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES October 06, 2021 04:01 PM Eastern Daylight Time HALIFAX
...more
(16)
•••
kindvalue
X
View Profile
View Bullboard History
Comment by
kindvalue
on Oct 05, 2021 12:33pm
RE:merck drug cost
mingzhu you are pretty well the only one posting on this site the company has been heavily critisized for its lack of IR, little effort little money spent thoughts on this ? more
...more
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Oct 04, 2021 4:07pm
merck drug cost
$700 per person,(5 days course), 2 doses per day. If APli can sell half of that price, the revenue will be huge.
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Oct 03, 2021 9:45pm
incoming catalysts
1, Shedding sub-study results in mid Oct 2, early results of P3 trial by the end of Oct 3, final complete results by the end of Nov 4, submitting doc of anti-fungus drug for approval by FDA by the end
...more
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Oct 01, 2021 11:05pm
excellent article on MERCK's drug and ours
https://www.biorxiv.org/content/10.1101/2020.12.10.419242v5
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Comment by
mingzhu
on Oct 01, 2021 10:32am
RE:it is stupidity sellers are selling on this news
it is hard to say if FDA think Merck's 755 patients are statistically significant.
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Oct 01, 2021 10:07am
it is stupidity sellers are selling on this news
https://www.cnbc.com/2021/10/01/merck-to-seek-emergency-authorization-for-oral-covid-19-treatment.html It has 775 patients for the tiral, we have over 2000. we could be faster if we had that number
...more
(329)
•••
Sheshe1234
X
View Profile
View Bullboard History
Comment by
Sheshe1234
on Sep 30, 2021 1:25pm
RE:prediction for SP
sounds like a dream
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Sep 30, 2021 12:22pm
insiders own 20m out of 61m, 31%, and new aiPharma 19%
that is over 51%. not many shares are on the market. Burton, Jolyon Relationship as filed with regulators: 6 Latest filing date: November 24, 2020 Control or Direction Common Shares Class A Common
...more
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Sep 29, 2021 12:42pm
prediction for SP
1, $5 if the results are great 2, $10 if FDA approves emergency use.
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Sep 29, 2021 9:16am
news
[url=https://ceo.ca/@businesswire/appili-therapeutics-and-aipharma-announce-strategic]https://ceo.ca/@businesswire/appili-therapeutics-and-aipharma-announce-strategic[/url] Global Response Aid (GRA
...more
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Sep 23, 2021 8:36am
news
https://ca.finance.yahoo.com/news/appili-therapeutics-announces-last-patient-114800129.html
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Sep 20, 2021 8:44am
news
https://ca.finance.yahoo.com/news/appili-therapeutics-announces-agreement-fujifilm-114400928.html
(29)
•••
mingzhu
X
View Profile
View Bullboard History
Post by
mingzhu
on Sep 17, 2021 8:44am
news
https://ca.finance.yahoo.com/news/appili-therapeutics-announces-completion-patient-111700422.html
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income